US 12,144,583 B2
Diffusion tensor MR to monitor glymphatic system
Sheldon Jordan, Pacific Palisades, CA (US)
Assigned to Synaptec Network, Inc., Santa Monica, CA (US)
Filed by Synaptec Network, Inc, Santa Monica, CA (US)
Filed on Mar. 20, 2020, as Appl. No. 16/824,718.
Claims priority of provisional application 62/821,673, filed on Mar. 21, 2019.
Prior Publication US 2020/0297211 A1, Sep. 24, 2020
Int. Cl. A61B 5/00 (2006.01); A61B 5/055 (2006.01); G01R 33/48 (2006.01); G01R 33/56 (2006.01); G06T 7/00 (2017.01); G16H 10/60 (2018.01); G16H 30/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01)
CPC A61B 5/0042 (2013.01) [A61B 5/055 (2013.01); A61B 5/4842 (2013.01); A61B 5/4848 (2013.01); G01R 33/4806 (2013.01); G01R 33/5608 (2013.01); G06T 7/0016 (2013.01); G06T 7/97 (2017.01); G16H 10/60 (2018.01); G16H 30/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G06T 2207/10088 (2013.01); G06T 2207/30016 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of treating a neurological disease in a region of a patient's brain, comprising:
taking a first image and a second image of the region of the patient's brain via magnetic resonance imaging (MRI);
comparing the first image with the second image to detect a change in an extracellular space in the region of the patient's brain;
administering a therapeutic agent responsive to the neurological disease when, during a time period, the change in the extracellular space indicates increased exposure of the therapeutic agent to the region of the patient's brain; and
administering a secondary agent that increases or decreases the change in the extracellular space;
wherein the first image is taken while the patient is awake, the second image is taken while the patient is asleep, and the first and second images are taken less than thirty minutes apart.